those who meet any of the following conditions will be excluded: 1. those who are known to be allergic to the test drug and any component in the preparation, or other similar drugs; 2. complications requiring surgery within 7 days, or complication considered life-threatening within 28 days; 3. received treatment with sars-cov-2 neutralizing antibody drugs before screening; 4. convalescent plasma from recovered patients before screening; 5. patients who took anti-sars-cov-2 drugs within 48 hours before enrollment, including but not limited to paxlovid (nirmatrelvir/ritonavir), azvudine, molnupiravir, etc. 6. on the day of enrollment, meet the diagnostic criteria for severe/critical new coronavirus pneumonia; 7. suspected to have been combined with active bacteria, fungi, viruses or other infections other than the new coronavirus; 8. those who plan to become pregnant, are pregnant, or are breastfeeding; 9. participated in clinical trials of sars-cov-2 neutralizing antibody drugs within 180 days before screening or participated in clinical trials of other drugs or medical devices within 4 weeks before screening; 10. suffering from severe neurological diseases (epilepsy, convulsions or convulsions) or mental illness, with a family history of mental illness; 11. suffering from other serious diseases that are not controlled, such as severe cardiovascular and cerebrovascular diseases, liver and kidney diseases, endocrine system diseases; or other diseases that the researchers judge are not suitable for participating in the study (such as currently uncontrolled autoimmune diseases, etc. ); 12. other conditions that the researcher believes are not suitable for participating in this study due to various reasons.

those who meet any of the following conditions will be excluded: 1. those who are known to be allergic to the test drug and any component in the preparation, or other similar drugs; 2. complications requiring surgery within 7 days, or complication considered life-threatening within 28 days; 3. received treatment with sars-cov-2 neutralizing antibody drugs before screening; 4. convalescent plasma from recovered patients before screening; 5. patients who took anti-sars-cov-2 drugs within 48 hours before enrollment, including but not limited to paxlovid (nirmatrelvir/ritonavir), azvudine, molnupiravir, etc. 6. on the day of enrollment, meet the diagnostic criteria for severe/critical new coronavirus pneumonia; 7. suspected to have been combined with active bacteria, fungi, viruses or other infections other than the new coronavirus; 8. those who plan to become pregnant, are pregnant, or are breastfeeding; 9. participated in clinical trials of sars-cov-2 neutralizing antibody drugs within 180 days before screening or participated in clinical trials of other drugs or medical devices within 4 weeks before screening; 10. suffering from severe neurological diseases (epilepsy, convulsions or convulsions) or mental illness, with a family history of mental illness; 11. suffering from other serious diseases that are not controlled, such as severe cardiovascular and cerebrovascular diseases, liver and kidney diseases, endocrine system diseases; or other diseases that the researchers judge are not suitable for participating in the study (such as currently uncontrolled autoimmune diseases, etc. ); 12. other conditions that the researcher believes are not suitable for participating in this study due to various reasons.

those who meet any of the following conditions will be excluded: those who are known to be allergic to the test drug and any component in the preparation, or other similar drugs; complications requiring surgery within 7 days, or complication considered life-threatening within 28 days; received treatment with sars-cov-2 neutralizing antibody drugs before screening; convalescent plasma from recovered patients before screening; patients who took anti-sars-cov-2 drugs within 48 hours before enrollment, including but not limited to paxlovid (nirmatrelvir/ritonavir), azvudine, molnupiravir, etc. on the day of enrollment, meet the diagnostic criteria for severe/critical new coronavirus pneumonia; suspected to have been combined with active bacteria, fungi, viruses or other infections other than the new coronavirus; those who plan to become pregnant, are pregnant, or are breastfeeding; participated in clinical trials of sars-cov-2 neutralizing antibody drugs within 180 days before screening or participated in clinical trials of other drugs or medical devices within 4 weeks before screening; suffering from severe neurological diseases (epilepsy, convulsions or convulsions) or mental illness, with a family history of mental illness; suffering from other serious diseases that are not controlled, such as severe cardiovascular and cerebrovascular diseases, liver and kidney diseases, endocrine system diseases; or other diseases that the researchers judge are not suitable for participating in the study (such as currently uncontrolled autoimmune diseases, etc. ); other conditions that the researcher believes are not suitable for participating in this study due to various reasons.

those who meet any of the following conditions will be excluded: those who are known to be allergic to the test drug and any component in the preparation, or other similar drugs; complications requiring surgery within 7 days, or complication considered life-threatening within 28 days; received treatment with sars-cov-2 neutralizing antibody drugs before screening; convalescent plasma from recovered patients before screening; patients who took anti-sars-cov-2 drugs within 48 hours before enrollment, including but not limited to paxlovid (nirmatrelvir/ritonavir), azvudine, molnupiravir, etc. on the day of enrollment, meet the diagnostic criteria for severe/critical new coronavirus pneumonia; suspected to have been combined with active bacteria, fungi, viruses or other infections other than the new coronavirus; those who plan to become pregnant, are pregnant, or are breastfeeding; participated in clinical trials of sars-cov-2 neutralizing antibody drugs within 180 days before screening or participated in clinical trials of other drugs or medical devices within 4 weeks before screening; suffering from severe neurological diseases (epilepsy, convulsions or convulsions) or mental illness, with a family history of mental illness; suffering from other serious diseases that are not controlled, such as severe cardiovascular and cerebrovascular diseases, liver and kidney diseases, endocrine system diseases; or other diseases that the researchers judge are not suitable for participating in the study (such as currently uncontrolled autoimmune diseases, etc. ); other conditions that the researcher believes are not suitable for participating in this study due to various reasons.

those who meet any of the following conditions will be excluded: those who are known to be allergic to the test drug and any component in the preparation, or other similar drugs; complications requiring surgery within 7 days, or complication considered life-threatening within 28 days; received treatment with sars-cov-2 neutralizing antibody drugs before screening; convalescent plasma from recovered patients before screening; on the day of enrollment, meet the diagnostic criteria for severe/critical new coronavirus pneumonia; suspected to have been combined with active bacteria, fungi, viruses or other infections other than the new coronavirus; those who plan to become pregnant, are pregnant, or are breastfeeding; participated in clinical trials of sars-cov-2 neutralizing antibody drugs within 180 days before screening or participated in clinical trials of other drugs or medical devices within 4 weeks before screening; suffering from severe neurological diseases (epilepsy, convulsions or convulsions) or mental illness, with a family history of mental illness; suffering from other serious diseases that are not controlled, such as severe cardiovascular and cerebrovascular diseases, liver and kidney diseases, endocrine system diseases; or other diseases that the researchers judge are not suitable for participating in the study (such as currently uncontrolled autoimmune diseases, etc. ); other conditions that the researcher believes are not suitable for participating in this study due to various reasons.

those who meet any of the following conditions will be excluded: those who are known to be allergic to the test drug and any component in the preparation, or other similar drugs; complications requiring surgery within 7 days, or complication considered life-threatening within 28 days; received treatment with sars-cov-2 neutralizing antibody drugs before screening; convalescent plasma from recovered patients before screening; on the day of enrollment, meet the diagnostic criteria for severe/critical new coronavirus pneumonia; suspected to have been combined with active bacteria, fungi, viruses or other infections other than the new coronavirus; those who plan to become pregnant, are pregnant, or are breastfeeding; participated in clinical trials of sars-cov-2 neutralizing antibody drugs within 180 days before screening or participated in clinical trials of other drugs or medical devices within 4 weeks before screening; suffering from severe neurological diseases (epilepsy, convulsions or convulsions) or mental illness, with a family history of mental illness; suffering from other serious diseases that are not controlled, such as severe cardiovascular and cerebrovascular diseases, liver and kidney diseases, endocrine system diseases; or other diseases that the researchers judge are not suitable for participating in the study (such as currently uncontrolled autoimmune diseases, etc. ); other conditions that the researcher believes are not suitable for participating in this study due to various reasons.